News from eli lilly and company A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 19, 2019, 12:05 ET Lilly Declares Third-Quarter 2019 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2019 of $0.645 per share on outstanding...


Jun 14, 2019, 06:45 ET Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study ...


Jun 11, 2019, 03:00 ET Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz® (ixekizumab). Patients with...


Jun 10, 2019, 21:30 ET Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta®...


Jun 10, 2019, 13:00 ET New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria

A new post-hoc analysis of data from the EMPA-REG OUTCOME® trial indicates a consistent effect of Jardiance® (empagliflozin) on reducing...


Jun 09, 2019, 19:30 ET Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes

Detailed results from REWIND, the Trulicity® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major...


Jun 09, 2019, 11:30 ET Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions

Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog® ...


Jun 08, 2019, 20:30 ET Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions®

Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce...


Jun 06, 2019, 06:45 ET Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology

Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the Annual European Congress of...


Jun 05, 2019, 06:45 ET Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology

Eli Lilly and Company (NYSE: LLY) will present data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 24th World Congress of...


Jun 04, 2019, 21:01 ET FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm)...


Jun 04, 2019, 07:30 ET U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of...


May 31, 2019, 07:00 ET Hurricane Season is Almost Here. Are You Ready?

The 2019 Atlantic hurricane season begins June 1. With natural disasters and extreme weather on the rise, it's critical to be prepared and ready to...


May 30, 2019, 16:15 ET Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Joshua...


May 29, 2019, 16:15 ET Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio

Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations...


May 28, 2019, 07:54 ET Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion...


May 22, 2019, 06:30 ET Lilly's Lower-Priced Insulin Now Available

Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin ...


May 16, 2019, 16:30 ET Lilly to Participate in UBS Global Healthcare Conference

Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Christi Shaw, president of Lilly...


May 15, 2019, 17:00 ET Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer

Eli Lilly and Company (NYSE: LLY) today announced that data from a number of studies across the company's oncology product portfolio will be...


May 15, 2019, 06:30 ET Lilly to Participate in Bank of America Merrill Lynch Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019....


May 13, 2019, 06:45 ET Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10...


May 06, 2019, 14:16 ET Lilly Declares Second-Quarter 2019 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding ...


May 06, 2019, 06:45 ET AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups

Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase...


May 02, 2019, 06:45 ET Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio

Eli Lilly and Company (NYSE: LLY) announced today it will present 19 scientific abstracts for Emgality® (galcanezumab-gnlm) and lasmiditan at the...


Apr 30, 2019, 06:25 ET Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health

Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2019. $ in millions, except per share data First Quarter ...